Offer - Urjas Oil for just ₹ 1 X
Cyclid 2.5 Tablet is a prescription drug, available for use as Tablet. It is typically used for the treatment of Parkinson's Disease.
The correct dosage of Cyclid 2.5 Tablet depends on the patient's age, gender, and medical history. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. This information has been provided in detail in the dosage section.
Some other side effects of Cyclid 2.5 Tablet have been listed ahead. These side effects of Cyclid 2.5 Tablet are usually temporary and subside with the completion of treatment. Please speak with your doctor if these side effects worsen or persist for a longer duration.
It is also important to note that Cyclid 2.5 Tablet has a Moderate effect for pregnant women and Severe effect on lactating mothers. Further, the section on Cyclid 2.5 Tablet related warnings talks about Cyclid 2.5 Tablet's effects on the liver, heart and kidney.
Cyclid 2.5 Tablet is contraindicated in people with pre-existing medical conditions like Tardive Dyskinesia, Glaucoma as it can result in adverse effects. Some other conditions that can be affected by Cyclid 2.5 Tablet are listed in the contraindications section below.
Drug interactions for Cyclid 2.5 Tablet have been reported in the medical literature. A complete list of these interactions is given below.
You should also be aware that Cyclid 2.5 Tablet is not safe while driving, and is not addiction.
Cyclid 2.5 Tablet is used to treat the following -
Main Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Cyclid 2.5 Tablet safe for pregnant women?
Cyclid can have harmful effects in pregnant women. If you experience any discomfort after using Cyclid, then discontinue the use and take your doctor's advice.
Is the use of Cyclid 2.5 Tablet safe during breastfeeding?
Taking Cyclid may lead to serious side effects if you are breastfeeding. Cyclid should not be taken by breastfeeding women unless prescribed by the doctor.
What is the effect of Cyclid 2.5 Tablet on the Kidneys?
Very few cases of side effects of Cyclid on kidney have been reported.
What is the effect of Cyclid 2.5 Tablet on the Liver?
Cyclid may cause harmful effects on liver. if you feel it's having any such effect, then stop taking this drug, and restart only on your doctor's advice.
What is the effect of Cyclid 2.5 Tablet on the Heart?
Very few cases of side effects of Cyclid on the heart have been reported.
Cyclid 2.5 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Moderate
Mild
If you are suffering from any of the following diseases, you should not take Cyclid 2.5 Tablet unless your doctor advises you to do so -
Is this Cyclid 2.5 Tablet habit forming or addictive?
No, there is no any evidence that Cyclid 2.5 Tablet is addictive.
Is it safe to drive or operate heavy machinery when consuming?
No, you should not drive or operate heavy machinery after taking Cyclid 2.5 Tablet as you may feel sleepy.
Is it safe?
Yes, but take Cyclid 2.5 Tablet only as per medical advice.
Is it able to treat mental disorders?
Yes, taking Cyclid 2.5 Tablet can treat mental disorders.
Interaction between Food and Cyclid 2.5 Tablet
Taking Cyclid 2.5 Tablet with food is safe.
Interaction between Alcohol and Cyclid 2.5 Tablet
Consuming Cyclid 2.5 Tablet with alcohol can have many serious effects on your body.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Kemadrin (procyclidine hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 433